Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

HealthRX vs YOURx Health

Two GLP-1 desks, one scoreboard. We put HealthRX and YOURx Health head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 7 · Grade B

HealthRX

Visit HealthRX Full brief →
vs
No. 317 · Grade C

YOURx Health

Visit YOURx Health Full brief →

The verdict

HealthRX takes this head-to-head.

HealthRX scores 86 to 61 on our six-factor Brief Score — A LegitScript-certified, physician-supervised desk (healthrx.com) whose real hook is breadth: injectable and a rare oral GLP tablet, on both molecules, with transparent no-insurance monthly pricing.

That doesn't make YOURx Health a bad call — it's best for readers who want md integrations-network glp-1 with included lab monitoring. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
85
58
Supply Reliability
85
60
Transparency
83
72
Access Breadth
91
56
Clinical Oversight
89
74
Track Record
81
47
HealthRXBrief Score 86 · 61YOURx Health

Price, coverage & the tracker

HealthRXYOURx Health
Brief Score86/100 (B)61/100 (C)
Semaglutide$189/moFrom $159/mo (compounded oral)
Tirzepatide$349/moFrom $179/mo (compounded oral)
CoverageNot publicly listedCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualYesYes
On the trackerStableprice stableNewnew to the tracker, no prior reading

HealthRX: Company-stated tiers held flat this cycle; the LegitScript badge and a rare oral GLP tablet are the draw, but some tiers are self-reported rather than checkout-verified.

YOURx Health: New to the tracker on 1 August 2026. The published line reads From $159/mo (compounded oral) at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.